TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

3.900 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 07, 2024

Via Benzinga

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

September 26, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

September 23, 2024

From TriSalus Life Sciences

Via Business Wire

TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 15, 2024

TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

TriSalus Reports Q2 2024 Financial Results and Business Update

August 15, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

August 01, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

July 01, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

June 26, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

June 03, 2024

From TriSalus Life Sciences

Via Business Wire

Crude Oil Rises 1%; Verastem Shares Slide ↗

May 24, 2024

Via Benzinga

Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 24, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 24, 2024

Via Benzinga

Nasdaq Gains 1%; Intuit Shares Plunge ↗

May 24, 2024

Via Benzinga

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

May 24, 2024

From TriSalus Life Sciences

Via Business Wire

TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 ↗

May 15, 2024

TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

TriSalus Reports Q1 2024 Financial Results and Business Update

May 15, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

May 07, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

May 06, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

April 30, 2024

From TriSalus Life Sciences

Via Business Wire

TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 ↗

April 01, 2024

TLSI stock results show that TriSalus Life Sciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

April 01, 2024

From TriSalus Life Sciences

Via Business Wire

Earnings Scheduled For April 1, 2024 ↗

April 01, 2024

Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million.

Via Benzinga

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

March 26, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

March 21, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

March 07, 2024

From TriSalus Life Sciences

Via Business Wire

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

February 29, 2024

From TriSalus Life Sciences

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 14, 2023

Via Benzinga

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

November 14, 2023

From TriSalus Life Sciences Inc.

Via Business Wire

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

November 07, 2023

From TriSalus Life Sciences Inc.

Via Business Wire

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

November 04, 2023

From TriSalus Life Sciences Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.